{"entity":{"type":"insider","cik":"0001654430","url":"/insider/0001654430","json_url":"/insider/0001654430.json","name":"Morrison Briggs","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":41,"n_filings":25,"first":"2019-05-13","last":"2026-03-09","span_basis":"filed_date"},"name_variants":[{"name":"Morrison Briggs","source":"filing","n_filings":25,"first_seen":"2019-05-13","last_seen":"2026-03-09"}],"transactions":[{"id":5882638,"accession":"0001628280-26-016003","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-26-016003","line_url":"/filing/0001628280-26-016003#line-1","is_derivative":false,"issuer_cik":"0001654430","issuer_name":"ARVINAS, INC.","issuer_ticker":"ARVN","issuer_name_source":null,"issuer_url":"/issuer/0001654430","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20000.0,"shares_display":"20,000","price_per_share":13.4035,"price_display":"13.40","price_state":"stated","total_value":268070.0,"total_display":"268,070.00","total_whole":"268,070","shares_owned_after":96021.0,"shares_owned_after_display":"96,021","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-06","filed_date":"2026-03-09","scope":"insider"},{"id":5055800,"accession":"0001628280-25-042536","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-25-042536","line_url":"/filing/0001628280-25-042536#line-1","is_derivative":false,"issuer_cik":"0001654430","issuer_name":"ARVINAS, INC.","issuer_ticker":"ARVN","issuer_name_source":null,"issuer_url":"/issuer/0001654430","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30000.0,"shares_display":"30,000","price_per_share":7.567,"price_display":"7.57","price_state":"stated","total_value":227010.0,"total_display":"227,010.00","total_whole":"227,010","shares_owned_after":76021.0,"shares_owned_after_display":"76,021","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-22","filed_date":"2025-09-24","scope":"insider"},{"id":8498644,"accession":"0001562180-23-006262","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-23-006262","line_url":"/filing/0001562180-23-006262#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":52855.0,"shares_display":"52,855","price_per_share":18.2651,"price_display":"18.27","price_state":"stated","total_value":965401.8605,"total_display":"965,401.86","total_whole":"965,402","shares_owned_after":17836.0,"shares_owned_after_display":"17,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-09","filed_date":"2023-08-10","scope":"insider"},{"id":8688405,"accession":"0001562180-23-005845","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-23-005845","line_url":"/filing/0001562180-23-005845#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":52855.0,"shares_display":"52,855","price_per_share":20.3967,"price_display":"20.40","price_state":"stated","total_value":1078067.5785,"total_display":"1,078,067.58","total_whole":"1,078,068","shares_owned_after":17836.0,"shares_owned_after_display":"17,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-07-10","filed_date":"2023-07-11","scope":"insider"},{"id":8038974,"accession":"0001562180-23-005057","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001562180-23-005057","line_url":"/filing/0001562180-23-005057","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":52855.0,"shares_display":"52,855","price_per_share":21.1791,"price_display":"21.18","price_state":"stated","total_value":1119421.3305,"total_display":"1,119,421.33","total_whole":"1,119,421","shares_owned_after":17836.0,"shares_owned_after_display":"17,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-09","filed_date":"2023-06-09","scope":"insider","n_lines":2},{"id":8210466,"accession":"0001562180-23-004032","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-23-004032","line_url":"/filing/0001562180-23-004032#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":52855.0,"shares_display":"52,855","price_per_share":21.4072,"price_display":"21.41","price_state":"stated","total_value":1131477.556,"total_display":"1,131,477.56","total_whole":"1,131,478","shares_owned_after":17836.0,"shares_owned_after_display":"17,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-09","filed_date":"2023-05-10","scope":"insider"},{"id":7977889,"accession":"0001562180-23-003521","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-23-003521","line_url":"/filing/0001562180-23-003521#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":52855.0,"shares_display":"52,855","price_per_share":19.5296,"price_display":"19.53","price_state":"stated","total_value":1032237.008,"total_display":"1,032,237.01","total_whole":"1,032,237","shares_owned_after":17836.0,"shares_owned_after_display":"17,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-04-10","filed_date":"2023-04-12","scope":"insider"},{"id":8210149,"accession":"0001562180-23-002770","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-23-002770","line_url":"/filing/0001562180-23-002770#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (President, Head of R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":52854.0,"shares_display":"52,854","price_per_share":22.5276,"price_display":"22.53","price_state":"stated","total_value":1190673.7704,"total_display":"1,190,673.77","total_whole":"1,190,674","shares_owned_after":17836.0,"shares_owned_after_display":"17,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-13","filed_date":"2023-03-14","scope":"insider"},{"id":8006922,"accession":"0001562180-23-001117","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-23-001117","line_url":"/filing/0001562180-23-001117#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (President, Head of R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":52854.0,"shares_display":"52,854","price_per_share":26.8269,"price_display":"26.83","price_state":"stated","total_value":1417908.9726,"total_display":"1,417,908.97","total_whole":"1,417,909","shares_owned_after":17836.0,"shares_owned_after_display":"17,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-06","filed_date":"2023-02-08","scope":"insider"},{"id":6627259,"accession":"0001562180-22-006788","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001562180-22-006788","line_url":"/filing/0001562180-22-006788#line-4","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (President, Head of R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":59649.0,"shares_display":"59,649","price_per_share":23.2529,"price_display":"23.25","price_state":"stated","total_value":1387012.2321,"total_display":"1,387,012.23","total_whole":"1,387,012","shares_owned_after":17836.0,"shares_owned_after_display":"17,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-09-20","filed_date":"2022-09-21","scope":"insider"},{"id":6627253,"accession":"0001562180-22-006788","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-22-006788","line_url":"/filing/0001562180-22-006788#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (President, Head of R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":114339.0,"shares_display":"114,339","price_per_share":23.0284,"price_display":"23.03","price_state":"stated","total_value":2633044.2276,"total_display":"2,633,044.23","total_whole":"2,633,044","shares_owned_after":17836.0,"shares_owned_after_display":"17,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-09-19","filed_date":"2022-09-21","scope":"insider"},{"id":6275487,"accession":"0001562180-22-006706","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001562180-22-006706","line_url":"/filing/0001562180-22-006706","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (President, Head of R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":125000.0,"shares_display":"125,000","price_per_share":23.2195,"price_display":"23.22","price_state":"stated","total_value":2902437.5,"total_display":"2,902,437.50","total_whole":"2,902,438","shares_owned_after":17836.0,"shares_owned_after_display":"17,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-09-16","filed_date":"2022-09-16","scope":"insider","n_lines":2},{"id":6275479,"accession":"0001562180-22-006706","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001562180-22-006706","line_url":"/filing/0001562180-22-006706#line-4","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (President, Head of R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":66775.0,"shares_display":"66,775","price_per_share":24.2012,"price_display":"24.20","price_state":"stated","total_value":1616035.13,"total_display":"1,616,035.13","total_whole":"1,616,035","shares_owned_after":17836.0,"shares_owned_after_display":"17,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-09-15","filed_date":"2022-09-16","scope":"insider"},{"id":6275475,"accession":"0001562180-22-006706","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-22-006706","line_url":"/filing/0001562180-22-006706#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (President, Head of R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":87645.0,"shares_display":"87,645","price_per_share":23.7989,"price_display":"23.80","price_state":"stated","total_value":2085854.5905,"total_display":"2,085,854.59","total_whole":"2,085,855","shares_owned_after":17836.0,"shares_owned_after_display":"17,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-09-14","filed_date":"2022-09-16","scope":"insider"},{"id":6225645,"accession":"0001562180-22-005475","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-22-005475","line_url":"/filing/0001562180-22-005475#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (President, Head of R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":62292.0,"shares_display":"62,292","price_per_share":18.9981,"price_display":"19.00","price_state":"stated","total_value":1183429.6452,"total_display":"1,183,429.65","total_whole":"1,183,430","shares_owned_after":17836.0,"shares_owned_after_display":"17,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-01","filed_date":"2022-07-05","scope":"insider"},{"id":6948571,"accession":"0001209191-22-024674","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-22-024674","line_url":"/filing/0001209191-22-024674","is_derivative":false,"issuer_cik":"0001654430","issuer_name":"ARVINAS, INC.","issuer_ticker":"ARVN","issuer_name_source":null,"issuer_url":"/issuer/0001654430","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20960.0,"shares_display":"20,960","price_per_share":66.4415955629771,"price_display":"66.44","price_state":"stated","total_value":1392615.843,"total_display":"1,392,615.84","total_whole":"1,392,616","shares_owned_after":19976.0,"shares_owned_after_display":"19,976","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-14","filed_date":"2022-04-18","scope":"insider","n_lines":3},{"id":6515303,"accession":"0001562180-22-003223","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001562180-22-003223","line_url":"/filing/0001562180-22-003223#line-6","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (President, Head of R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3128.0,"shares_display":"3,128","price_per_share":18.2928,"price_display":"18.29","price_state":"stated","total_value":57219.8784,"total_display":"57,219.88","total_whole":"57,220","shares_owned_after":17836.0,"shares_owned_after_display":"17,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-04","filed_date":"2022-04-05","scope":"insider"},{"id":6515298,"accession":"0001562180-22-003223","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001562180-22-003223","line_url":"/filing/0001562180-22-003223","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (President, Head of R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":101045.0,"shares_display":"101,045","price_per_share":17.452771097035974,"price_display":"17.45","price_state":"stated","total_value":1763515.2555,"total_display":"1,763,515.26","total_whole":"1,763,515","shares_owned_after":17836.0,"shares_owned_after_display":"17,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-01","filed_date":"2022-04-05","scope":"insider","n_lines":3},{"id":6767058,"accession":"0000899243-22-002557","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-22-002557","line_url":"/filing/0000899243-22-002557","is_derivative":false,"issuer_cik":"0001654430","issuer_name":"ARVINAS, INC.","issuer_ticker":"ARVN","issuer_name_source":null,"issuer_url":"/issuer/0001654430","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20960.0,"shares_display":"20,960","price_per_share":65.55441630248092,"price_display":"65.55","price_state":"stated","total_value":1374020.5657,"total_display":"1,374,020.57","total_whole":"1,374,021","shares_owned_after":35789.0,"shares_owned_after_display":"35,789","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-14","filed_date":"2022-01-19","scope":"insider","n_lines":4},{"id":5496460,"accession":"0001562180-21-007810","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-21-007810","line_url":"/filing/0001562180-21-007810#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":35156.0,"shares_display":"35,156","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":703120.0,"total_display":"703,120.00","total_whole":"703,120","shares_owned_after":48336.0,"shares_owned_after_display":"48,336","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-17","filed_date":"2021-12-20","scope":"insider"},{"id":4146231,"accession":"0001562180-21-006038","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001562180-21-006038","line_url":"/filing/0001562180-21-006038#line-4","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50.0,"shares_display":"50","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":1000.0,"total_display":"1,000.00","total_whole":"1,000","shares_owned_after":48336.0,"shares_owned_after_display":"48,336","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-20","filed_date":"2021-09-21","scope":"insider"},{"id":4146223,"accession":"0001562180-21-006038","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-21-006038","line_url":"/filing/0001562180-21-006038#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":70262.0,"shares_display":"70,262","price_per_share":20.068,"price_display":"20.07","price_state":"stated","total_value":1410017.816,"total_display":"1,410,017.82","total_whole":"1,410,018","shares_owned_after":48336.0,"shares_owned_after_display":"48,336","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-17","filed_date":"2021-09-21","scope":"insider"},{"id":4550124,"accession":"0000899243-21-006954","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-006954","line_url":"/filing/0000899243-21-006954#line-1","is_derivative":false,"issuer_cik":"0001654430","issuer_name":"Codiak BioSciences, Inc.","issuer_ticker":"CDAK","issuer_name_source":null,"issuer_url":"/issuer/0001654430","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4761.0,"shares_display":"4,761","price_per_share":21.0,"price_display":"21.00","price_state":"stated","total_value":99981.0,"total_display":"99,981.00","total_whole":"99,981","shares_owned_after":4761.0,"shares_owned_after_display":"4,761","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-17","filed_date":"2021-02-17","scope":"insider"},{"id":4992418,"accession":"0001562180-21-001044","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-21-001044","line_url":"/filing/0001562180-21-001044#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":35156.0,"shares_display":"35,156","price_per_share":20.5485,"price_display":"20.55","price_state":"stated","total_value":722403.066,"total_display":"722,403.07","total_whole":"722,403","shares_owned_after":48336.0,"shares_owned_after_display":"48,336","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-08","filed_date":"2021-02-10","scope":"insider"},{"id":2461314,"accession":"0001562180-20-006681","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001562180-20-006681","line_url":"/filing/0001562180-20-006681#line-4","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17466.0,"shares_display":"17,466","price_per_share":20.0568,"price_display":"20.06","price_state":"stated","total_value":350312.0688,"total_display":"350,312.07","total_whole":"350,312","shares_owned_after":46565.0,"shares_owned_after_display":"46,565","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-10","filed_date":"2020-11-12","scope":"insider"},{"id":2461307,"accession":"0001562180-20-006681","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-20-006681","line_url":"/filing/0001562180-20-006681#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":62938.0,"shares_display":"62,938","price_per_share":20.0398,"price_display":"20.04","price_state":"stated","total_value":1261264.9324,"total_display":"1,261,264.93","total_whole":"1,261,265","shares_owned_after":46565.0,"shares_owned_after_display":"46,565","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-09","filed_date":"2020-11-12","scope":"insider"},{"id":2783329,"accession":"0001209191-20-038972","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-038972","line_url":"/filing/0001209191-20-038972#line-1","is_derivative":false,"issuer_cik":"0001654430","issuer_name":"Repare Therapeutics Inc.","issuer_ticker":"RPTX","issuer_name_source":null,"issuer_url":"/issuer/0001654430","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4800.0,"shares_display":"4,800","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":96000.0,"total_display":"96,000.00","total_whole":"96,000","shares_owned_after":4800.0,"shares_owned_after_display":"4,800","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-06-23","filed_date":"2020-06-25","scope":"insider"},{"id":3312105,"accession":"0001209191-20-021125","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-021125","line_url":"/filing/0001209191-20-021125#line-1","is_derivative":false,"issuer_cik":"0001654430","issuer_name":"ARVINAS, INC.","issuer_ticker":"ARVN","issuer_name_source":null,"issuer_url":"/issuer/0001654430","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2500.0,"shares_display":"2,500","price_per_share":38.18,"price_display":"38.18","price_state":"stated","total_value":95450.0,"total_display":"95,450.00","total_whole":"95,450","shares_owned_after":29520.0,"shares_owned_after_display":"29,520","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-03-24","filed_date":"2020-03-25","scope":"insider"},{"id":3068202,"accession":"0001562180-20-000891","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-20-000891","line_url":"/filing/0001562180-20-000891#line-1","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12500.0,"shares_display":"12,500","price_per_share":8.0,"price_display":"8.00","price_state":"stated","total_value":100000.0,"total_display":"100,000.00","total_whole":"100,000","shares_owned_after":43900.0,"shares_owned_after_display":"43,900","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-04","filed_date":"2020-02-05","scope":"insider"},{"id":8630402,"accession":"0001562180-19-005140","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-19-005140","line_url":"/filing/0001562180-19-005140#line-1","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11000.0,"shares_display":"11,000","price_per_share":5.4,"price_display":"5.40","price_state":"stated","total_value":59400.0,"total_display":"59,400.00","total_whole":"59,400","shares_owned_after":31400.0,"shares_owned_after_display":"31,400","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-10-10","filed_date":"2019-10-11","scope":"insider"},{"id":7854662,"accession":"0001562180-19-002780","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-19-002780","line_url":"/filing/0001562180-19-002780#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7200.0,"shares_display":"7,200","price_per_share":7.294,"price_display":"7.29","price_state":"stated","total_value":52516.8,"total_display":"52,516.80","total_whole":"52,517","shares_owned_after":20400.0,"shares_owned_after_display":"20,400","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-13","filed_date":"2019-05-13","scope":"insider"},{"id":7854660,"accession":"0001562180-19-002780","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-19-002780","line_url":"/filing/0001562180-19-002780#line-1","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001654430","owner_name":"Morrison Briggs","owner_display_name":"Morrison Briggs","owner_url":"/insider/0001654430","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":13200.0,"shares_display":"13,200","price_per_share":7.555,"price_display":"7.56","price_state":"stated","total_value":99726.0,"total_display":"99,726.00","total_whole":"99,726","shares_owned_after":13200.0,"shares_owned_after_display":"13,200","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-09","filed_date":"2019-05-13","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":41,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":9,"open_market":true},{"code":"S","label":"Open-market sale","n":32,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":41},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001655759","name":"ARVINAS, INC.","url":"/issuer/0001655759","role":"Director","n_filings":5,"first_seen":"2020-03-25","last_seen":"2026-03-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001395937","name":"Syndax Pharmaceuticals Inc","url":"/issuer/0001395937","role":"Director, Officer (President, Head of R&D)","n_filings":18,"first_seen":"2019-05-13","last_seen":"2023-08-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001659352","name":"Codiak BioSciences, Inc.","url":"/issuer/0001659352","role":"Director","n_filings":1,"first_seen":"2021-02-17","last_seen":"2021-02-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001808158","name":"Repare Therapeutics Inc.","url":"/issuer/0001808158","role":"Director","n_filings":1,"first_seen":"2020-06-25","last_seen":"2020-06-25"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001654430","retrieved_at":"2026-08-25T19:35:10+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}